Alpine Peaks Capital’s Maravai LifeSciences MRVI Stock Holding History

Alpine Peaks Capital’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$283K	Buy	100,000 +3,100	+3%	+$10.5K	0.29%	21
2025 Q4	$315K	Sell	96,900 -47,600	-33%	-$160K	0.3%	21
2025 Q3	$415K	Buy	+144,500	New	+$369K	0.36%	24

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alpine Peaks Capital's MRVI Position: Q2 2025 in Review

Alpine Peaks Capital sold out of Maravai LifeSciences (MRVI) in Q2 2025, closing a stake of 242,000 shares — an estimated $535K sold.

Alpine Peaks Capital first reported a position in MRVI in Q4 2022 and held it in 10 quarters. The position peaked at $4.09M in Q2 2023. 150 funds tracked by Wall St. Rank hold MRVI as of Q2 2025.

Alpine Peaks Capital reported no remaining Maravai LifeSciences position as of Q2 2025 after selling out during the quarter.
Alpine Peaks Capital sold 242,000 Maravai LifeSciences shares in Q2 2025, an estimated $535K.
Alpine Peaks Capital first reported a position in Maravai LifeSciences in Q4 2022 and held it in 10 quarters.
Alpine Peaks Capital's Maravai LifeSciences position peaked at $4.09M in Q2 2023.
150 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2025.

Based on Alpine Peaks Capital's 13F filing for Q2 2025, filed 14 Aug 2025.